These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21837697)

  • 21. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
    Boonkitticharoen V; Kulapaditharom B; Leopairut J; Kraiphibul P; Larbcharoensub N; Cheewaruangroj W; Chintrakarn C; Pochanukul L
    Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1305-11. PubMed ID: 19075127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.
    Rizzardi C; Leocata P; Ventura L; Zweyer M; Brollo A; Schneider M; Melato M
    Anticancer Res; 2009 Apr; 29(4):1137-42. PubMed ID: 19414356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
    Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monocyte tumor necrosis factor production in head and neck squamous cell carcinoma.
    Gallo O; Pinto S; Boccuzzi S; Dilaghi M; Gallina E; Attanasio M; Gori AM; Martini F; Abbate R
    Laryngoscope; 1992 Apr; 102(4):447-50. PubMed ID: 1556897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
    Sanlioglu AD; Koksal IT; Ciftcioglu A; Baykara M; Luleci G; Sanlioglu S
    J Urol; 2007 Jan; 177(1):359-64. PubMed ID: 17162091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels.
    Verim A; Turan S; Farooqi AA; Kahraman OT; Tepe-Karaca C; Yildiz Y; Naiboglu B; Ozkan NE; Ergen A; Isitmangil GA; Yaylim I
    Asian Pac J Cancer Prev; 2014; 15(24):10697-703. PubMed ID: 25605161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
    Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
    Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Ozdogan M; Suleymanlar I; Balci MK; Griffith TS; Sanlioglu S
    Pancreas; 2009 Mar; 38(2):154-60. PubMed ID: 18981952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
    Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma.
    Madan R; Brandwein-Gensler M; Schlecht NF; Elias K; Gorbovitsky E; Belbin TJ; Mahmood R; Breining D; Qian H; Childs G; Locker J; Smith R; Haigentz M; Gunn-Moore F; Prystowsky MB
    Head Neck; 2006 Nov; 28(11):1018-27. PubMed ID: 16783828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells.
    Hu JK; Yang K; Li CM; Zhang B; Chen ZX; Chen XZ; Chen JP
    Oncol Rep; 2009 Mar; 21(3):681-8. PubMed ID: 19212626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
    McCarthy MM; Sznol M; DiVito KA; Camp RL; Rimm DL; Kluger HM
    Clin Cancer Res; 2005 Jul; 11(14):5188-94. PubMed ID: 16033835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.